PT909315E - Cck-2, um receptor da tirosina cinase - Google Patents

Cck-2, um receptor da tirosina cinase

Info

Publication number
PT909315E
PT909315E PT95900749T PT95900749T PT909315E PT 909315 E PT909315 E PT 909315E PT 95900749 T PT95900749 T PT 95900749T PT 95900749 T PT95900749 T PT 95900749T PT 909315 E PT909315 E PT 909315E
Authority
PT
Portugal
Prior art keywords
mck
relates
receptor
cinase
thyrosin
Prior art date
Application number
PT95900749T
Other languages
English (en)
Inventor
Axel Ullrich
Frauke H E Alves
Original Assignee
Max Planck Gesellschaft
E V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22547060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT909315(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft, E V filed Critical Max Planck Gesellschaft
Publication of PT909315E publication Critical patent/PT909315E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT95900749T 1993-11-16 1994-11-16 Cck-2, um receptor da tirosina cinase PT909315E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/153,397 US6051397A (en) 1993-11-16 1993-11-16 DNA encoding MCK-10, a novel receptor tyrosine kinase

Publications (1)

Publication Number Publication Date
PT909315E true PT909315E (pt) 2005-10-31

Family

ID=22547060

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95900749T PT909315E (pt) 1993-11-16 1994-11-16 Cck-2, um receptor da tirosina cinase

Country Status (10)

Country Link
US (4) US6051397A (pt)
EP (1) EP0909315B1 (pt)
AT (1) ATE296351T1 (pt)
AU (2) AU8143894A (pt)
CA (1) CA2187152A1 (pt)
DE (1) DE69434385T2 (pt)
DK (1) DK0909315T3 (pt)
ES (1) ES2242956T3 (pt)
PT (1) PT909315E (pt)
WO (2) WO1995014089A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627733B2 (en) 1993-06-14 2003-09-30 Jeffrey D. Johnson Receptor tyrosine kinase with a discoidin-type binding domain
AU697142B2 (en) * 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
US6022694A (en) * 1997-04-04 2000-02-08 Regeneron Pharmaceuticals, Inc. Assay for ligands to tyrosine kinase receptors
US6482607B1 (en) * 1998-06-16 2002-11-19 Rmf Dictagene S.A. Expression vector for use in a one-step purification protocol
GB9820392D0 (en) 1998-09-19 1998-11-11 Eastman Kodak Co Novel yellow couplers providing images with improved sharpness and photographic elements containing them
AUPQ873300A0 (en) * 2000-07-12 2000-08-03 Medvet Science Pty. Ltd. A binding motif of a receptor (2)
EP1218404A4 (en) * 1999-09-15 2004-04-07 Medvet Science Pty Ltd REASON FOR BINDING A RECEIVER
GB2357084A (en) * 1999-12-06 2001-06-13 Amersham Pharm Biotech Uk Ltd A hydrophobic carrier peptide
US20090176722A9 (en) * 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
US6365355B1 (en) 2000-03-28 2002-04-02 The Regents Of The University Of California Chimeric proteins for detection and quantitation of DNA mutations, DNA sequence variations, DNA damage and DNA mismatches
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
WO2002046416A2 (en) * 2000-12-04 2002-06-13 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20070025997A1 (en) * 2002-04-03 2007-02-01 Usha Nagavarapu Use of biomolecular targets in the treatment and visualization of brain tumors
ATE411395T1 (de) * 2003-10-24 2008-10-15 Oncalis Ag Verfahren zur identifizierung und/oder validierung von rezeptortyrosinkinase-inhibitoren
US20090142345A1 (en) * 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
US8652472B2 (en) * 2006-12-05 2014-02-18 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2518157A1 (en) 2011-04-26 2012-10-31 Sanofi Test Systems and methods for identifying a compound altering cellular DDR activity
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013155365A1 (en) * 2012-04-12 2013-10-17 University Of Maryland Markers for diagnosing amyotrophic lateral sclerosis
AU2013365742B2 (en) 2012-12-19 2016-11-24 Novartis Ag Autotaxin inhibitors
KR101462329B1 (ko) 2013-01-30 2014-11-21 중앙대학교 산학협력단 디스코이딘 도메인 리셉터 2의 ｊｍ2 도메인의 발현 촉진제를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물
US20160168119A1 (en) 2013-07-18 2016-06-16 Novartis Ag Autotaxin inhibitors
US9763957B2 (en) 2013-07-18 2017-09-19 Novartis Ag Autotaxin inhibitors
EP3134398A1 (en) 2014-04-24 2017-03-01 Novartis Ag Autotaxin inhibitors
WO2019071262A1 (en) * 2017-10-06 2019-04-11 The Regents Of The University Of California RAPID SITU DETECTION OF DNA AND RNA

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004606A (en) * 1986-09-24 1991-04-02 Hybritech Incorporated Non-covalent antibody-anthracycline immunocomplexes
NL8900529A (nl) 1989-03-03 1990-10-01 Eurodiagnostics B V Werkwijze en kit voor het bepalen van tyrosine fosforylerende en defosforylerende activiteit.
CA2062377A1 (en) 1991-03-21 1992-09-22 Mariano Barbacid Method for detection of neuroactive substances
GB9314271D0 (en) * 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse

Also Published As

Publication number Publication date
AU8143994A (en) 1995-06-06
CA2187152A1 (en) 1995-05-26
US5677144A (en) 1997-10-14
DK0909315T3 (da) 2005-09-12
ES2242956T3 (es) 2005-11-16
DE69434385T2 (de) 2006-05-24
US20060147372A1 (en) 2006-07-06
WO1995014089A2 (en) 1995-05-26
ATE296351T1 (de) 2005-06-15
DE69434385D1 (de) 2005-06-30
US6897029B1 (en) 2005-05-24
US6051397A (en) 2000-04-18
WO1995014088A1 (en) 1995-05-26
EP0909315B1 (en) 2005-05-25
WO1995014089A3 (en) 1995-06-15
AU8143894A (en) 1995-06-06
EP0909315A2 (en) 1999-04-21

Similar Documents

Publication Publication Date Title
PT909315E (pt) Cck-2, um receptor da tirosina cinase
AP1486A (en) Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use.
TWI262914B (en) Compounds and pharmaceutical compositions for inhibiting protein kinases
ATE292623T1 (de) 2-indolinonderivate als modulatoren der proteinkinase-ativität
AP2001002341A0 (en) Diaminothiazoles and their use for inhibiting protein kinases.
DE69232537T2 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
TR199700644T1 (xx) Serotonin-ili�kili sistemler �zerinde etkiye sahip bile�ikler.
DE69233478T8 (de) Neue menschliche cdc25 gene, kodierte produkte und ihre verwendung
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
NO985376D0 (no) Kinolinkarboksamider som TNF-inhibitorer og som PDA-IV inhibitorer
EP0991628A4 (en) CHINOLINE AND CHINOXALINE COMPOUNDS THAT INHIBIT THE GROWTH FACTOR AND / OR PDGF AND LCK TYROSINE KINASE FROM BLOOD PLATES
BR0308339A (pt) Indazóis substituìdos com uma atividade anticancerosa
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
BR0317548A (pt) Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
CO4700426A1 (es) Ligandos especificos del neuropeptido y1
ATE179211T1 (de) Menschliche il-3-varianten
NO177214C (no) Anordning ved en stol som omfatter understöttende og fjærende elementer som tillater ettergivende bevegelse av stolen i forhold til et underlag
DE69333660D1 (de) Pct-65 serotonin rezeptor
WO2021202780A3 (en) Methods and compositions for treating cancer
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
DE69333261D1 (de) KLONIERUNG UND EXPRESSION VON DEM beta APP-C100 REZEPTOR
ATE190663T1 (de) Cd69 - transkriptionsregulierende elemente
PT870015E (pt) Novas xilanases os genes que as codificam e as suas utilizacoes
ATE226446T1 (de) Muteine von wildtyp-cytokinen und ihre verwendung als immunogene